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Rezumat. Apariția  unor noi forme de tuberculoză, inclusiv rezistente la tratament, precum și complexitatea tratamentului antituber-
culos rămân factori de provocare în obținerea și cercetarea de  agenți antimicobacterieni noi din diferite clase, cu efecte maxime chiar 
și împotriva bacilului drog-rezistent. În cadrul echipei de sinteză a Laboratorului de Sinteză Organică și Biofarmaceutică de la Institutul 
de Chimie a fost realizată sinteza unui șir de oxadiazoli, pentru care a fost demonstrată acțiunea antimicobacteriană pronunțată in vitro 
și toxicitatea mică a acestora.  Au fost obținuți compuși noi - derivați de propiltiodiazolochinazolin-onă sub formă de sare  anorganică 
(sulfat) și complex cu ciclodextrina, pentru care s-a efectuat un screening toxicologic, antimicrobian și antituberculos. Totodată, s-au 
evaluat proprietățile fizico-chimice ale compușilor: punctul de topire, solubilitatea în diverși solvenți la trei nivele de pH, pierderile la 
uscare (umiditate) și higroscopicitatea, analiza spectrală în IR. Studiile, redate în acest articol vor contribui la selectarea compusului 
optimal obținut din acest grup, cu perspectiva elaborării unui nou remediu antituberculos.
Cuvinte cheie: tuberculoză, propiltiodiazolochinazolin-onă, proprietăți fizico-chimice.
Abstract. The emergence of new forms of tuberculosis, including resistant to treatment, as well as the complexity of antituberculous 
treatment remain challenging factors in obtaining and researching new antimycobacterial agents of different classes, with maximum 
effects even against the drug-resistant bacillus. Within the synthesis team of the Organic and Biopharmaceutical Synthesis Laboratory 
of the Institute of Chemistry, a series of oxadiazoles was synthesized for which the pronounced antimycobacterial action in vitro was 
proved. The low toxicity was demonstrated as well. New compounds of propylthiodiazolokinazolin-one derivatives in the form of inor-
ganic salt (sulfate) and cyclodextrin complex were obtained. The toxicological, antimicrobial and antituberculous screening on these 
substances was performed. At the same time, the physico-chemical properties of the compounds were evaluated: melting point, solu-
bility in various solvents at three pH levels, drying losses (humidity) and hygroscopicity, spectral analysis in IR. The studies presented in 
this article will contribute to the selection of the optimal compound obtained from this group, with the perspective to develop a new 
antituberculosis product.
Keywords: tuberculosis, propylthiodiazolokinazolin-one, physicochemical properties.
Introduction
Nowadays, one third of the people in the all world is 
infected with Mycobacterium tuberculosis (MTB) and, 
therefore, they are at risk of developing active tuberculosis 
(TB). More than 99% of deaths and 95% of new TB cases 
happen in low- and middle-developed countries. The Re-
public of Moldova is placed by the World Health Organi-
zation (WHO) in the top of 18 priority countries fighting 
against tuberculosis in the European region. At the same 
time, the Republic of Moldova is one of the 27-th countries 
with a high incidence of multidrug-resistant tuberculosis 
[1]. Thus, one of the main aims of the National Tuberculo-
sis Control Program for 2016-2020 is to elaborate the anti-
tubercular treatment regimens by using the new antituber-
culosis medications, applying in children [2].
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The bacterial resistance to antibiotics is constantly 
growing both in Europe and in the world. It represents an 
extremely complex and important problem in the whole 
world. According to the recent data, there are more than 
240000 people annually exposed to the bacterial infection 
resistant to standard antibiotic treatment lines in Europe 
and the USA. Unfortunately, about 50000 of them cul-
minated with death. Due to COVID-19 this situation is 
getting worse [3, 4]. Despite the urgent need for new an-
tibacterial treatment options, there are a small number of 
new antimycobacterial medications used in clinical trials. 
Unfortunately, infections caused by surgical interventions 
or hospitalizations still represent the essential problem that 
can lead to reducing the effectiveness of the most advanced 
therapies for treating initial medical problems. Moreover, 
the cost of drug-resistant infections treatment is increas-
ing by 1.5 billion euros annually. As a result, the design 
and synthesis of new compounds with effective antibacte-
rial activity on multi-drug-resistant bacteria (MDR) is not 
only a desideratum but an obligation [3, 4]. 
According to the recent reports, it was found that in 
the Republic of Moldova 10 people were diagnosed with 
tuberculosis daily, every tenth was suffering from multi-
drug-resistant tuberculosis, (MDR TB) and one person 
died daily caused by tuberculosis progresses, unless health 
services maintained and strengthened [5]. Tuberculosis is 
among the top causes of death as a result of infectious dis-
eases in our country. Nowadays, there are no original au-
tochthonous antimycobacterial drugs. On the other hand, 
the remedies used have a number of disadvantages: they 
are expensive, the spectrum of activity is limited, drug-re-
sistance is developed by bacilli. The advanced bibliography 
analysis of the recent years leads to the conclusion that the de-
velopment and appearance of new antimycobacterial classes 
of medications were behind the development of mycobacte-
rial resistance. As a result, the therapeutic arsenal for treating 
MDR bacterial infections requires new molecules with supe-
rior efficacy to conventional ones. This is also highlighted in 
the World Health Organization’s 2020 report recommending 
“stimulating innovation, research and development of new 
tools” to control bacterial resistance [6].
The COVID-19 is a pandemic that seriously threatens 
those small recent advances in reducing the incidence of 
TB disease. Due to disrupted health services, it has been 
estimated that the overall number of deaths from TB could 
increase by about 0.2-0.4 million just in 2020, caused by 
decreasing the number of diagnosed and treated people by 
about 25-50% in only 3 months [4].
The research of new compounds with anti-tuberculosis 
activity is a priority direction in the international and na-
tional scientific world. Thus, due to synthesis team of the 
Laboratory of Organic Synthesis and Biopharmaceuticals 
within the Institute of Chemistry, a series of aryl-oxadia-
zoles were obtained, including propylthiohinothiadiazolol, 
that represents one of the most active substances in this 
group [7, 8, 9, 10, 11, 12]. Obtaining inorganic salts, com-
plexing with cyclodextrins are attempts to optimize bio-
availability and to use these new derivatives as medicinal 
substances for the antituberculosis treatment, including 
multi-drug resistant forms.
The purpose of this study was to evaluate some physi-
co-chemical parameters of three compounds from the pro-
pylthiodiazoloquinazolinone group.
Materials and Methods
Test substances. Three synthetic compounds from the 
propylthiodiazolokinazolinone group, obtained in the 
Laboratory of Organic Synthesis and Biopharmaceuticals 
within the Institute of Chemistry from the Republic of 
Moldova, were used as a test material: Propylthiohinothia-
diazole (MF-001); Propylthiohinothiadiazole sulfate (MF-
001-H2SO4); Propylthiohinothiadiazole complex with cy-
clodextrins (β-CD-MF-001); as internal reference standard 
was used 2- (propylthio) 5H- [1, 3, 4] thiadiasolo- [2,3-b] 
quinasolin-5-one substance, purified by recrystallization 
in the Laboratory of Analysis, Standardization and Con-
trol of Medications (LASCM) within the Scientific Center 
of Medicines of the Nicolae Testemitanu State University 
of Medicine and Pharmacy from the Republic of Moldova 
(concentration 99.98%) [13]. 
Melting behavior/Melting point. The melting point was 
determined in the LASCM using A. KRÜSS KPS Melting-
Point Meter KPS II device. Each substance was measured 
three times, according to the requirements of the Europe-
an Pharmacopoeia (Ph. Eur.) 10.0 [14]. The propriety of 
MF-001 and β-CD-MF-001 in melting was also studied by 
the thermal analysis method – differential scanning calo-
rimetry (DSC), using the Mettler Toledo STARe Thermal 
Analysis system, version 6.0 (Schwerzenbach, Switzer-
land). About 2-5 mg of substances were examined in the 
temperature range from 25 to 300°C in argon flux (10 L/h). 
The heating rate was 5°C / min.
IR spectral analysis. The βCD + MF-001 binary com-
plex was analyzed by the FT-IR (Fourier-transform in-
frared) spectrophotometer: SPECTRUM 100 (PERKIN 
ELMER, USA) at the Institute of Chemistry. Due to this 
method, which makes use of totally attenuated reflection, 
the substance was described and characterized. The bi-
nary mixtures were prepared by weighing the appropriate 
amounts of analyzed substances and homogenizing in ag-
ate mortar for 20 minutes. The FT-IR spectrum of MF-001 
was compared to the spectrum of the binary mixture βCD 
+ MF-001 (1: 1) and βCD + 1MF-001 + H2O (1: 1: 18). All 
FTIR spectra were recorded in the range from 4000 cm-1 
to 400 cm-1.
Solubility. Solubility determination was measured by 
the department of pharmaceutical technology of the edu-
cational institution “Belarusian State Medical University” 
(BSMU). The tests were carried out at temperatures of 200C 
and 370C; solvents used: purified water, ethyl alcohol, di-
methylsulfoxide (DMSO), hexane, chloroform, 0,1 M sodi-
um hydroxide solution, 0,1 M hydrochloric acid solution. 
Dissolving media used: 0,1 M hydrochloric acid buffer M, 
with pH = 1.2, phosphate buffer with pH = 4.5, phosphate 
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buffer with pH = 6.8. The measurements were performed 
on the ERWEKA DT 800 Dissolution tester; the volume of 
the dissolution medium 250, 500 and 900 ml; temperature 
of the dissolution medium 37 ± 0.5 ° С; rotational speed 50 
rotations per minute; sampling interval: 15, 30, 45, 60, 90, 
120 minutes; number of samples tested in each dissolution 
medium: 6. Quantitative evaluation of the substances was 
performed spectrophotometrically on the Sagu 50 spectro-
photometer, using buffer solutions with different pH val-
ues  as comparison solutions.
The ability of PEG to solubilize the substances in the 
suspensions was determined. The suspensions were pre-
pared by stirring 0.01 g of substances in 4 ml of water in a 
graduated tube. PEG was added dropwise until the volume 
doubled (8 ml).
Loss on drying. The determination of humidity was per-
formed by the drying method, according to the require-
ments of Ph. Eur. 10 [14]. The exact amounts of substances 
were dried to a constant mass in the drying cabinet model 
2B-151. Drying losses were calculated in %.
Hygroscopicity. The exact masses of the substances 
were placed in plastic ampoules and placed for 6 hours in 
a desiccator at the bottom where water was poured. The 
desiccator was hermetically covered with a lid to prevent 
the entering water from the outside. The ampoules were 
weighed every 2 hours. The amount of water absorbed was 
expressed in %.
Results and discussions
Melting behavior / Melting point.
The simplest parameter to estimate the purity of a solid 
organic substance is the melting point. The melting point is 
defined as the temperature at which the solid is in equilib-
rium with its melt. The pure substances have a fixed melt-
ing temperature, its exact determination (approx. 0.01°C) 
being possible only by plotting the melting curves. Impuri-
ties, even in very small quantities, lower the melting tem-
perature and widen the melting range (1°C). This phenom-
enon is used to determine the identity of two substances 
with the same melting temperature.
The melting point was determined for all three test sub-
stances, according to the requirements of Ph. Eur. 10 [14]. 
As a result of the carried out investigations the close values 
of the melting range for MF-001 and β-CD-MF-001 were 
found. The β-CD-MF-001 melted with carbonization and 
the MF-001-H2SO4 melted under structural changes (the 
value of the melting point is not stable). The results of the 
determinations are shown in table 1.
To determine the degree of MF-001 capture by cyclo-
dextrins and the formation of the β-CD-Mf-001 complex, 
the DSC curves of the pure substance and the 1: 1 binary 
mixture were recorded. It is known that when the „guest” 
molecule is captured in the cyclodextrin cavity, its melting, 
boiling or sublimation point is usually shifted to another 
temperature, during which the cyclodextrin decomposes. 
Thus, for a 1: 1 molar ratio, certain endothermic or exo-
thermic peaks can be observed in the DSC curves, which 
means that the physical mixing method does not provide a 
complete encapsulation of the binary mixture in the cyclo-
dextrin cavity (fig. 1).
The thermograms showed very fine changes in the 
melting temperature of the binary system at lower values, 
and the reduction in the melting enthalpies at decreasing 
amounts of the substance. This phenomenon may be an in-
dication of the dispersion of molecule crystals in the β-CD 
matrix, and the formation of very energetic crystals of MF-
001. At the same time, the substance maintains a certain 
level of crystallinity in the crushed product.
FT-IR spectral analysis.
FT-IR spectroscopy is a modern spectral optical meth-
od, which is used to identify the molecular structures of 
medicinal substances based on the interactions of infrared 
light with some functional groups, bonds and structural 
units that are reflected in spectra. The interpretation of 
the FT-IR spectra of the test substances is a very impor-
tant part. The identification of the chemical structure is 
based on the values of vibration frequencies characteristic 
of functional groups, shown in the table [16]. In particular, 
there is an increased interest for the molecules of MF-001 
and the β-CD-MF-001 complex, because valence displace-
ments that characterize the formation bonds of the com-
plex are illustrated in the spectra.
According to the fig. 2 and fig.3, it was found that the 
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Fig. 1. DSC thermograms of substance MF-001 
and β-CD-MF-001 complex
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system spectrum presents mainly the spectra sum of its 
components. However, some of the absorption bands of 
the individual compounds may disappear from the sys-
tem spectrum, for example, the band at 756 cm-1 in the 
β-CD spectra, which corresponds to the vibrations δCCO 
+ δCCH. The FT-IR spectra recorded for the MF-001 + 
βCD binary system shows displacements of the absorp-
tion bands characteristic of the constituents. Thus, the ab-
sorption band characteristic of the –OH functional group, 
observed in the complex spectrum, has been shifted to a 
lower frequency. On the other hand, for the deformation 
vibrations of the C-H bonds in the βCD structure (1407, 
1335, 1296, 1251 cm-1) a displacement can be observed at 
higher wave numbers (table 2).
Table 2. Characteristic infrared absorption bands of 
functional groups
Group Assignment Range of absorption 
Intensity of 
bands
-C-S- ν C-S 683,9 medium narrow
-CH2- Scissoring βs 1463,4 medium narrow
-C=O ν –C=O 1704,9 strong 
-C=N- ν -C=N 1608,3 strong
C6H5 ν -CH 1484,7 &3070,6 different
CH3 ν -CH 1332,6 medium
Solubility.
The studies were made of the complete characteriza-
tion of the degree of solubilization of the test substances 
by using polar, organic, polymeric, greasy solvents. These 
studies are particularly important for predicting bioavail-
ability, but also for the preformulation stage of a possible 
pharmaceutical form. The results of the determinations are 
shown in tables 3 and 4. According to tables 3 and 4, it was 
found that the dissolution behavior of substances in differ-
ent solvents has varied as a result of the different chemical 
structure. Thus, MF-001 is freely soluble in DMSO, PEG 
400 and Polysorbate 20, is sparingly soluble in chloroform, 
while in the rest of the solvents it is very slightly soluble or 
practically insoluble.
Due to the form of salt of an inorganic acid, a good 
dissolution of MF-001-H2SO4 in water, alcohol and dis-
solution media with predetermined pH was expected, but 
it did not happen. The substance is freely soluble only in 
Polysorbate 20 and moderately soluble in DMSO, in the 
rest of the solvents it does not dissolve.
The β-CD-MF-001 complex is close in solubility to 
MF-001, being more advantageous in solubility in DMSO, 
Sunflower Oil and Polypropylene.
It is well-known that water-cosolvent mixtures are 
widely used in pharmaceutical technology to increase the 
solubility of poorly water-soluble medications during the 
pharmaceutical forms development. PEG 400 is most com-
Fig.2. FT-IR spectra of MF-001 (1) and β-CD (2)
Fig. 3. FT-IR spectra of βCD + MF-001 (1: 1) (1) and βCD + 1MF-001 + H2O (1: 1: 18) (2)
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monly used as a co-solvent in the development of oral and 
parenteral solutions. The ability of PEG to influence the 
dissolution degree in water of the test substances was stud-
ied (table 5). Thus, the compound β-CD-MF-001 is solubi-
lized immediately after the addition of the first portions of 
PEG 400, MF-001 becomes soluble after the addition of 3 
ml of PEG 400, while MF-001-H2SO4 remains insoluble.
The results obtained from the solubility study of the 
studied compounds represent as a basis for selecting the 
optimal solvents to develop the methods of analysis and for 
the technological stages of research of the test compounds.
Loss on drying.
The ability of substances to absorb water molecules 
from the air is an extremely important and decisive physi-
cal parameter in the selection and formulation of storage 
conditions.
The moisture content of the substances was determined 
by the drying method. MF-001 was found to be lost on 
drying 0,70 %, MF-001-H2SO4 – 5,77 % and β-CD-MF-001 
– 11,52 %. 
Hygroscopicity. 
The kinetics of water absorption capacity by the test 
substances were studied (table 6).
According to fig. 4 it was found that the phenomenon of 
moisture absorption by MF-001-H2SO4 was described by 
a linear function while in the case of MF-001 and β-CD-
MF-001 the absorption was described by a logarithmic 
function, that provided evidence for stronger hygroscopic 
properties of MF-001-H2SO4 than others. The studies of 
the influence of water on the integrity of substances have 
made it possible to establish preconditions for their store.
Table 3. The results of the determination of solubility in BSMU
Solvent MF-001 MF-001-H2SO4 β-CD-MF-001
1Purified water Practically insoluble Practically insoluble Practically insoluble
1Ethyl alcohol Practically insoluble Slightly soluble Practically insoluble
1DMSO Freely soluble Moderate soluble Very soluble
1Hexane Practically insoluble Slightly soluble Practically insoluble
1Chloroform Sparingly soluble Slightly soluble Practically insoluble
10.1 M sodium hydroxide solution Practically insoluble Practically insoluble Practically insoluble
10.1 M hydrochloric acid solution Practically insoluble Practically insoluble Practically insoluble
20.1 M hydrochloric acid buffer with  pH = 1.2 0,08 mg/ml 0,08 mg/ml 0,075 mg/ml
2Phosphate buffer solution with pH = 4.5 0,075 mg/ml 0,075 mg/ml 0,07 mg/ml
2Phosphate buffer solution with pH = 6.8 0,07 mg/ml 0,07 mg/ml 0,065 mg/ml
1determinations performed at 200C; 2determinations performed at 370C;
Table 4. The results of the determination of solubility in BSMU
Solvent MF-001 MF-001-H2SO4 β-CD-MF-001
Sunflower oil Sparingly soluble Practically insoluble Freely soluble
Polyethylene glycol (PEG) 400 Freely soluble Practically insoluble Freely soluble
Polypropylene Sparingly soluble Practically insoluble Freely soluble
Polysorbate 20 Freely soluble Freely soluble Freely soluble
Table 5. The results of the determination of PEG’s ability to influence the dissolution degree of test substances in water
The added amount of PEG MF-001 MF-001-H2SO4 β-CD-MF-001
1 ml Sparingly soluble Practically insoluble Freely soluble, complete solubilization
2 ml Moderate soluble Practically insoluble -
3 ml Soluble Practically insoluble -
4 ml Freely soluble Sparingly soluble -
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Conclusions
Evaluation of physicochemical parameters of the com-
pounds, such as, MF-001, MF-001-H2SO4 and β-CD-
Table 6. Determination of moisture absorption degree for the test substances
t, hours 0 2 4 6 % water
MF-001 mass, g 0,10006 0,12993 0,12997 0,12992 29,84
MF-001-H2SO4 mass, g 0,10016 0,12153 0,13618 0,14956 49,32
β-CD-MF-001 mass, g 0,10015 0,11135 0,11250 0,11258 12,41
y = 0,0219ln(x) + 0,1051
y = 0,0163x + 0,0861
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MF-001 MF-001-H2SO4 -CD-MF-001
Fig. 4. The curves describing the kinetics of water absorption 
by the test substances
During 6 hours the substances were weighed (every 2 
hours of storage).
MF-001 from the propylthiodiazolokinazolinone group 
- by determining the melting point and thermal behavior, 
analyzing the spectral behavior in the IR, determining the 
solubility in various solvents and dissolution media and 
the possibility of using PEG 400 as a co-solvent, evaluating 
the moisture and hygroscopicity of substances - highlight-
ed the distinct properties for each substance. 
These studies allow the continuation of research in or-
der to determine the bioavailability of these compounds, 
the selection of the substance with optimal properties and 
the development of a pharmaceutical form with antituber-
culous effect.
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